AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05135143 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant formula
Description: Administration of antioxidant formula 3 times a day and once daily.
Study NCT01874730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined epidural-general anesthesia (CEGA)
Description: Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
Study NCT00333320 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Percutaneous coronary interventions were performed following international guidelines. No additional intervention was performed in the control group.
Study NCT03816020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside
Description: Nicotinamide Riboside capsules 250mg x 2 BID
Study NCT03816020 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules BID
Study NCT01582490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Instillation - EXPAREL
Description: Intravenous (IV) morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
Study NCT01582490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infiltration - EXPAREL
Description: IV morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
Study NCT04750499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose tissue injection associated with endorectal advancement flap.
Description: Injection of adipose tissue will be associated with endorectal advancement flap technique. In blind fistulas and special cases, in which the flap is not indicated, alternative techniques will be used. In all cases, autologous, micro-fragmented and minimally manipulated adipose tissue, obtained with a standardized procedure, previously validated and authorized, will be injected. This procedure uses the Lipogems ® device (Lipogems International SpA, Milan, Italy), with which a well-characterized adipose tissue is obtained with the maximum safety guarantees.
Study NCT03048214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraclavicular nerve block
Description: Infraclavicular nerve block is a relatively safe and straightforward brachial plexus nerve block that can be used to provide intraoperative regional anaesthesia for upper limb surgeries from the elbow to fingers.
Study NCT03048214 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: General anaesthesia
Description: Usual practice for upper limb surgeries.
Study NCT00961675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FST201 (dexamethasone 0.1% with povidone-iodine 1%)
Description: 4 gtt BID (twice a day)
Study NCT00961675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprodex (Ciprofloxacin 0.3%; dexamethasone 0.1% )
Description: 4 gtt BID (twice a day)
Study NCT02872714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemigatinib
Description: Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.
Study NCT02872714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemigatinib
Description: Pemigatinib once a day by mouth continuously.
Study NCT03822091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, and randomised into group A and B. Group A patients will receive further higher doses of Terlipressin. The dose of Terlipressin will be increased by 1mg after 24 hrs if:~* the creatinine values decrease by \<12.5%~* MAP increase of \<10 mmHg~* urine output of \<200 ml in 4 hours.~Maximum terlipressin dose will be given upto 12 mg/day.Albumin will be administered in both arms according to standard protocol at the following dose :~1. 1st day - Albumin at 1 gram/kg - a maximum dose of 100grams can be given.~2. A dose of 20gram/day to 60gram/day in the following days.
Study NCT03822091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin and Noradrenaline
Description: Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, will be randomised into group A and B. Group B patients will be treated with~Terlipressin(2mg/24hr infusion- fixed dose) and Noradrenaline, which would be given as a continuous infusion at a starting dose of 0.5 mg/hr. The dose od noradrenaline will be increased every 24 hours in steps of 0.5 mg/hr, the maximum dose being 3 mg/hr IF:~* the creatinine values decrease by \<12.5%~* MAP increase of \<10 mmHg~* urine output of \<200 ml in 4 hours.
Study NCT02055924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib and immunochemotherapies
Description: Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
Study NCT04131660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVAPS-AE mode during NIV
Description: NIV will be setup in AVAPS-AE mode, with a Trilogy ventilation device (Respironics, Murrysville, PA). The range of positive expiratory pressure will be set between 4 and 14 cmH2O. The range of inspiratory pressure support will be set between 14 and 24 cmH2. The target tidal volume will be set to achieve 8 to 10 mL/kg of ideal body weight (Size (m) \* Size (m) \* 23).
Study NCT04131660 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: S/T mode during NIV
Description: NIV will be setup in ST mode, with a Trilogy ventilation device (Respironics, Murrysville, PA).~The physician will decide the level of positive expiratory pressure and of pressure support.
Study NCT04059835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OptiBra study
Description: compare two different bra after breast cancer surgery
Study NCT04059835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OptiBra study
Description: compare two different bra after breast cancer surgery
Study NCT02861807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain stimulation with mindfulness-based relapse prevention
Description: Participants will participate in weekly or twice weekly group mindfulness based relapse prevention (MBRP) + transcranial direct current stimulation (tDCS) intervention sessions for up to eight weeks. All participants will receive 8 two hour sessions of MBRP + tDCS, regardless of the group schedule. Subjects will receive 30 minutes of either active or sham tDCS stimulation, depending on their group assignment. After tDCS, sessions will include discussions of mindfulness as a means of coping with craving, cognitions, and emotions, role play exercises, and mindfulness practice.
Study NCT02861807 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Brain stimulation with mindfulness-based relapse prevention
Description: Participants will participate in weekly or twice weekly group mindfulness based relapse prevention (MBRP) + transcranial direct current stimulation (tDCS) intervention sessions for up to eight weeks. All participants will receive 8 two hour sessions of MBRP + tDCS, regardless of the group schedule. Subjects will receive 30 minutes of either active or sham tDCS stimulation, depending on their group assignment. After tDCS, sessions will include discussions of mindfulness as a means of coping with craving, cognitions, and emotions, role play exercises, and mindfulness practice.
Study NCT01686373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa Dose II Real tDCS
Description: 20 minutes of 1 milliamp active tDCS per treatment day (15 total sessions)
Study NCT01686373 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Activa Dose II Sham tDCS
Description: 20 minutes of sham stimulation per treatment day (15 total sessions)
Study NCT02731430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine
Description: received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
Study NCT02731430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrathecal saline
Description: received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
Study NCT04361773 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Treatment with a device with 144 light emitting diodes (LEDs) at wavelengths of 420, 660 and 850nm, 3J per point for 10 minutes.
Study NCT04361773 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Photobiomodulation
Description: Simulation of the LED application, with a device with external characteristics identical to that of the PBM group, for the same period of time.
Study NCT04151186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy
Description: Specification: 30 mL-100 mL, cell density of about (1-10) x10\^6 cells/ml in each bag, number of T-cells about (1-10) x10\^8 cells.) 300 ml for each infusion.~Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)\<71> and \<85> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 5-10 min.
Study NCT01874730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Volulyte® (6% HES 130/0.4 in balanced solution)
Description: For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg.
Study NCT01874730 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Volulyte® (6% HES 130/0.4 in balanced solution)
Description: For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg.
Study NCT01874730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Controlled Epidural Analgesia (PCEA)
Description: For the ERS Group, patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
Study NCT00736060 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Summary of clinical and laboratory data
Study NCT02631642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-689
Description: selective PI3Kδ inhibitor
Study NCT02631642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HMPL-689 placebo
Description: placebo of HMPL-689
Study NCT01559077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-TTR02
Description: Dose levels between 0.01 and 0.5 mg/kg by intravenous (IV) infusion
Study NCT01559077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study NCT02418884 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rosuvastatin
Description: CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
Study NCT02593695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Deep brain stimulation of bilateral nucleus accumbens
Study NCT02593695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
Study NCT03786588 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: The patients with the negative results of HPV infection, and assigned to different group according to the CPP manifestation.
Study NCT04162743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: take trazodone 100mg before polysomnography
Study NCT04162743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: take placebo oral tablet before polysomnography
Study NCT02946476 — intervention group
Intervention type: OTHER
Intervention: prognostic impact of non cardiac comorbidities
Study NCT03915132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 200mg/m2 IV on d1 of a week before radiotherapy , and 100mg/m2 IV on d1 weekly for 7 cycles
Study NCT03915132 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: VMAT
Description: Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume.
Study NCT01375062 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: analyse and proliferate the cells
Description: 1. Obtention of excess tissue from testicular biopsies and maintained in 4ºC until procedures.~2. Digestion of the biopsies through controlled enzymes~3. Replication of the cells~4. Selection undifferentiated cells~5. Expansion of the purification cells population~6. Characterization of the cell population~7. Assessment of pluripotent and germinal cell potential.~8. Possible maturation of the cells.
Study NCT00226499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix-tetra™
Description: 2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMRV Group
Study NCT00226499 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix™
Description: 2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMR Group and one dose administered subcutaneously at Day 0 to subjects in OKAH Group
Study NCT00226499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix™
Description: 2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMR Group and one dose administered subcutaneously at Day 0 to subjects in OKAH Group
Study NCT00226499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varilrix™
Description: 1 dose administered subcutaneously at Day 42 to subjects in OKAH Group
Study NCT00620945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine
Description: Use of Phenoxybenzamine:~Loading dose given at the time of going on CPB:~* For patients with obstructing lesions on systemic side:~  * 0.25 mg/kg dose in the bypass circuit~ * None intravenous~* For patients without obstructing left sided lesions:~  * 0.5 mg/kg in the bypass circuit~ * 0.5 mg/kg I.V. at cannulation~Maintenance dose given in the post-operative period:~* 0.3 mg/kg I.V. every 8 hours till oral intake is started or for first 48 hours~* 0.3 mg/kg P.O. every 8 hours for next 24 hours~* 0.15 mg/kg P.O. every 8 hours for next 24 hours and then stop~* Hold PBZ if the patient is on norepinephrine infusion or the mean arterial pressure is lower than that allowed for the age group
Study NCT02503540 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept
Description: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.
Study NCT04056260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG-NIR guided surgery
Description: ICG 0.5mg/ml x 0.5ml x 4 sites injection through intra-operative endoscopy
Study NCT01555749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC172-2021
Description: One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL
Study NCT01555749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: One injection administered subcutaneously (s.c., under the skin)
Study NCT05266690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Promitor 70
Description: Promitor 70: Resistant Dextrin with a complex structure containing 70% non-digestible dietary fiber
Study NCT00910481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-Aortic Balloon Pump
Description: Elective IABP insertion before PCI
Study NCT00511862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yttrium 90 glass microspheres
Description: 120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe
Study NCT01886976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-138 cells
Study NCT03566641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Description: The application of a vacuum across the surface of a wound through a foam dressing cut to fit the wound.
Study NCT03566641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care dressing
Description: The application of a standard care dressing (instead of negative pressure wound therapy) across the surface of wound.
Study NCT01871298 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pilot Website Evaluation Component
Description: The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
Study NCT04495712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: aldosterone blocker
Study NCT04495712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical in appearance to spironolactone study drug
Study NCT02349958 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HIPEC: MMC 30mg @ T0, 10mg @ T45min
Description: MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel
Study NCT02349958 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0
Description: Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min
Study NCT02349958 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HIPEC: CDDP 75 mg/m2 @T0
Description: Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0
Study NCT02349958 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
Description: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
Study NCT02281006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans-tympanic injection of a sodium thiosulfate gel
Description: A sodium thiosulfate hyaluronate gel will be prepared by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, DIN 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). On the day before each Cisplatin treatment an otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear.
Study NCT04544826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: JNJ-77474462 will be administered as SC injection.
Study NCT04544826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to JNJ-77474462 will be administered as SC injection.
Study NCT02844413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic interval training
Description: In the first group (G1), aerobic interval training (AIT) was undertaken for 5 months (40 professional AIT sessions performed two times per week in 50 minute sessions) and followed a specially developed program. The second control group (G2), did not attend any training sessions but received medical advice on how to maintain physical activity as outlined by JNC hypertension guidelines
Study NCT01644851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive function training
Description: Computer-based training in executive functions, administered via www.lumosity.com website.
Study NCT04535141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 MG
Description: It will be a de-identified pill created by investigational drug services at University of North Carolina
Study NCT04535141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It will be a de-identified pill created by investigational drug services at University of North Carolina
Study NCT05756595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)
Description: This group will inject once a week. Evaluation of pain score after 30 seconds and 3 hours.
Study NCT02288325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.